1.0 Hypothesis Moderate to severely active Crohn's disease (CD) will respond to treatment with Denosumab, (a monoclonal antibody to Receptor Activator of Nuclear factor-Kappa B ligand (RANKL)
The principal research questions to be addressed:
1. Determine if a single dose of Denosumab can induce a